Download PDF
CC BY 4.0 · TH Open 2019; 03(01): e67-e76
DOI: 10.1055/s-0039-1683970
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism

Juan J. López-Núñez
1   Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
,
Ricard Pérez-Andrés
2   Department of Radiology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
,
Pierpaolo Di Micco
3   Department of Internal Medicine and Emergency Room, Ospedale Buon Consiglio Fatebenefratelli, Naples, Italy
,
Sebastian Schellong
4   Department of Medical Clinic, Municipal Hospital of Dresden Friedrichstadt, Dresden, Germany
,
Covadonga Gómez-Cuervo
5   Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain
,
Joan Carles Sahuquillo
6   Department of Internal Medicine, Hospital Municipal de Badalona, Barcelona, Spain
,
Maurizio Ciammaichella
7   Department of Emergency Internal Medicine, Ospedale St. John, Rome, Italy
,
Maria del Valle Morales
8   Department of Internal Medicine, Hospital del Tajo, Madrid, Spain
,
Marijan Bosevski
9   University Cardiology Clinic, Faculty of Medicine, Skopje, Republic of Macedonia
,
Manuel Monreal
1   Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
,
and the RIETE Investigators › Author Affiliations
Further Information

Publication History

08 December 2018

06 February 2019

Publication Date:
20 March 2019 (online)

   Permissions and Reprints

Abstract

Background The efficacy and safety of the direct oral anticoagulants (DOACs) in fragile patients (age ≥ 75 years and/or creatinine clearance levels ≤ 50 mL/min and/or body weight ≤ 50kg) with venous thromboembolism (VTE) has not been evaluated.

Methods We used the RIETE database to compare the rates of the composite of VTE recurrences or major bleeding during anticoagulation in fragile patients with VTE, according to the use of DOACs or standard anticoagulant therapy.

Results From January 2013 to April 2018, 24,701 patients were recruited. Of these, 10,054 (41%) were fragile. Initially, 473 fragile patients (4.7%) received DOACs and 8,577 (85%) low-molecular-weight heparin (LMWH). For long-term therapy, 1,298 patients (13%) received DOACs and 5,038 (50%) vitamin K antagonists (VKAs). Overall, 95 patients developed VTE recurrences and 262 had major bleeding. Patients initially receiving DOACs had a lower rate of the composite outcome (hazard ratio [HR]: 0.32; 95% confidence interval [CI]: 0.08–0.88) than those on LMWH. Patients receiving DOACs for long-term therapy had a nonsignificantly lower rate of the composite outcome (HR: 0.70; 95% CI: 0.46–1.03) than those on VKAs. On multivariable analysis, patients initially receiving DOACs had a nonsignificantly lower risk for the composite outcome (HR: 0.36; 95% CI: 0.11–1.15) than those on LMWH, while those receiving DOACs for long-term therapy had a significantly lower risk (HR: 0.61; 95% CI: 0.41–0.92) than those on VKAs.

Conclusions Our data suggest that the use of DOACs may be more effective and safe than standard therapy in fragile patients with VTE, a subgroup of patients where the risk for bleeding is particularly high.

Keywords

venous thromboembolism - fragile patients - direct oral anticoagulants

Authors' Contributions

All the authors introduced patients in the database, performed the research, analyzed results, and reviewed the article. J. J. López-Núñez and M. Monreal designed the research and wrote the article.


* A full list of RIETE investigators is given in Appendix A.


 

  • References

  • 1 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 2 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedGoogle Scholar
  • 3 Moustafa F, Pierfranceschi MG, Di Micco P. , et al. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. Res Pract Thromb Haemost 2017; 1 (02) 172-179
    CrossrefPubMedGoogle Scholar
  • 4 Ruíz-Giménez N, Suárez C, González R. , et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (01) 26-31
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Muñoz-Torrero JF, Bounameaux H, Pedrajas JM. , et al; Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators. Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. J Vasc Surg 2011; 54 (06) , Suppl): 26S-32S
    CrossrefPubMedGoogle Scholar
  • 6 Jiménez D, de Miguel-Díez J, Guijarro R. , et al; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: Analysis from the RIETE Registry. J Am Coll Cardiol 2016; 67 (02) 162-170
    CrossrefPubMedGoogle Scholar
  • 7 Muriel A, Jiménez D, Aujesky D. , et al; RIETE Investigators. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63 (16) 1675-1683
    CrossrefPubMedGoogle Scholar
  • 8 Bikdeli B, Jimenez D, Hawkins M. , et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Bauersachs R, Agnelli G, Gitt AK. , et al; PREFER in VTE Scientific Steering Committee. The role of heparin lead-in in the real-world management of acute venous thromboembolism: the PREFER in VTE registry. Thromb Res 2017; 157: 181-188
    CrossrefPubMedGoogle Scholar
  • 10 Cohen AT, Gitt AK, Bauersachs R. , et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017; 117 (07) 1326-1337
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 12 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 13 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedGoogle Scholar
  • 14 Becattini C, Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol 2016; 67 (16) 1941-1955
    PubMedGoogle Scholar
  • 15 Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J. Effectiveness and safety of rivaroxaban versus warfarin in frail patients with venous thromboembolism. Am J Med 2018; 131 (08) 933.e1-938.e1
    PubMedGoogle Scholar
  • 16 Buchner DM, Wagner EH. Preventing frail health. Clin Geriatr Med 1992; 8 (01) 1-17
    PubMedGoogle Scholar
  • 17 Rockwood K, Song X, MacKnight C. , et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005; 173 (05) 489-495
    CrossrefPubMedGoogle Scholar
  • 18 Robinson TN, Eiseman B, Wallace JI. , et al. Redefining geriatric preoperative assessment using frailty, disability and co-morbidity. Ann Surg 2009; 250 (03) 449-455
    CrossrefPubMedGoogle Scholar
  • 19 Robinson TN, Wu DS, Pointer L, Dunn CL, Cleveland Jr JC, Moss M. Simple frailty score predicts postoperative complications across surgical specialties. Am J Surg 2013; 206 (04) 544-550
    CrossrefPubMedGoogle Scholar
  • 20 Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38 (02) 156-162
    PubMedGoogle Scholar
  • 21 Trujillo-Santos J, Di Micco P, Dentali F. , et al; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 2017; 117 (02) 382-389
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Monreal M, Falgá C, Valle R. , et al; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
    CrossrefPubMedGoogle Scholar
  • 23 Moustafa F, Stehouwer A, Kamphuisen P. , et al; RIETE Investigators. Management and outcome of major bleeding in patients receiving vitamin K antagonists for venous thromboembolism. Thromb Res 2018; 171: 74-80
    CrossrefPubMedGoogle Scholar